Multiple Sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: The duration of intervention in this clinical trial will be 12 weeks. Individuals receiving a magnesium supplement will receive 750 mg of magnesium per day in three
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: The individual's willingness to participate in the study Definite patients with relapsing-remitting MS based on the 2017 McDonald diagnostic criteria (20) who are on file at Sinai Hospital Age range 18-55 years EDSS less than 5.5 Education above diploma More than one month has passed since the last corticosteroid injection (pulse therapy) More than one month has passed since the last relapse of the disease
Exclusion criteria
Exclusion criteria: Suffering from another neurological disease other than MS Pregnancy or breastfeeding Suffering from chronic gastrointestinal, liver, kidney, heart, respiratory and cancer diseases Having a diet for any reason Suffering from severe psychological disorders such as major depression History of allergy to Magnesium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognition. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: MACFIMS test.;Anxiety. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: Beck Anxiety Inventory (BAI).;Depression. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: Beck Depression Inventory (BDI).;Fatigue. Timepoint: and at the end of the 12th week. Method of measurement: Fatigue Severity Scale (FSS) questionnaire.;Physical Activity. Timepoint: At the beginning of the study. Method of measurement: International Physical Activity Questionnaire (IPAQ).;Magnesium level. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: Blood test.;BDNF level. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: Blood test.;IL-6 level. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: Blood test.;Superoxide Dismutase II activity. Timepoint: At the beginning of the study and at the end of the 12th week. Method of measurement: Calorimetry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Rezaei Ahvanouei
Tehran University of Medical Sciences
Outcome results
None listed